EMBARGOED FOR RELEASE UNTIL 4 PM ET, March 11, 2013
New Add-On Drug May Improve Memory in People with Moderate Alzheimer鈥檚 Disease
SAN DIEGO -
A new drug may improve memory problems in people with moderate Alzheimer鈥檚 disease, according to a phase IIa study released today that will be presented at the 65th Annual Meeting in San Diego, March 16 to 23, 2013. The drug is called ORM-12741. The drug is the first to target a specific subtype of adrenergic receptors (alpha-2C) in the brain, which are believed to be involved in modulation of brain functions under stressful conditions, or the 鈥渇ight or flight鈥 response. For the clinical trial, 100 people with moderate Alzheimer鈥檚 disease were randomly given either 30 to 60 milligrams or 100 to 200 milligrams of ORM-12741 or matching placebo pill twice a day for three months as add-on therapy to a cholinesterase drug. Additionally, use of memantine was allowed. These are the other Alzheimer drugs currently on the market. Neither the researchers nor the participants knew which treatments participants were receiving. After three months, researchers retested several aspects of the participants鈥 memory and behavior. Those who took ORM-12741 tested higher on the tests of memory compared to those who received the placebo pill. At three months, the memory scores for those who received the placebo pill had worsened by 33 percent, whereas the scores improved by 4 percent for those who took ORM-12741. 鈥淐urrently, there are still only a handful of Alzheimer鈥檚 drugs on the market and they have only moderate effects on the symptoms of the disease,鈥 said study author Juha Rouru, MD, of Orion Pharma in Turku, Finland. 鈥淎nytime you have a drug that targets a new pathway in the brain and shows effectiveness in clinical trials, it is exciting.鈥 It is estimated that 13.8 million people will have Alzheimer鈥檚 disease by 2050. The study was supported by Orion Pharma. Learn more about Alzheimer鈥檚 disease at .
